Exposure vs. response of blood pressure in patients with rheumatoid arthritis following treatment with fostamatinib. (25th June 2014)

• Record Type: Journal Article
• Authors: Boström, Emma; Öhrn, Fredrik; Hanze, Eva; Sandström, Marie; Martin, Paul; Wählby‐Hamrén, Ulrika
• Is Part Of: Journal of clinical pharmacology. Volume 54:Number 12(2014:Dec.)
• Page Start: 1337
• Page End: 1346
• Publication Date: 2014-06-25
• Subjects: Pharmacology -- Periodicals; Pharmacology -- Periodicals; Pharmacology, Clinical -- Periodicals; 615.1
• DOI: 10.1002/jcph.341
• Languages: English
• ISSNs: 0091-2700

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <sec id="jcph341-sec-0001" sec-type="section"> <p>Fostamatinib is an oral spleen tyrosine kinase (SYK) inhibitor which has been evaluated as a potential treatment for rheumatoid arthritis (RA). Treatment with fostamatinib has been associated with an increase in blood pressure (BP). In this work, we present a pooled analysis of the pharmacokinetic–pharmacodynamic (PKPD) relationship for BP, based on 3 Phase III studies, aiming to increase the knowledge about fostamatinib's effect on BP in the RA population. Fostamatinib is rapidly and extensively converted to R406 after oral administration of fostamatinib, and the PK of R406 could be described by a two‐compartment population PK model with first order absorption, with an estimated CL/F of 18.7 L/h. Average steady‐state concentrations, predicted based on the individual CL/F estimates, were subsequently used in the PKPD analysis. The population PKPD analysis revealed a concentration dependent increase of BP with increasing R406 concentrations, where a power model and an E_max model best described the increase in SBP and DBP, respectively. The predicted increases were +5.2 mmHg for SBP and +4.2 mmHg for DBP, for a 100 mg bid dose. The impact of covariates on the PKPD relationship was investigated but covariates did only explain a minor part of the overall high variability in BP.</p> </sec> </abstract>